Objective Assessment of Retinal Function

2008 ◽  
pp. 1609-1632
Author(s):  
Michael A. Sandberg
Keyword(s):  
Objective Assessment ◽  
Retinal Function

scholarly journals Considerations about electroretinography in dogs

2004 ◽  
Vol 34 (1) ◽  
pp. 323-328 ◽  
Author(s):  
Arianne Pontes Oriá ◽  
Luiz Paulo Lázaro Júnior ◽  
Cristiane dos Santos Honsho ◽  
Francisco de Assis Dórea Neto ◽  
José Luiz Laus
Keyword(s):  
Diagnostic Tool ◽  
Objective Assessment ◽  
Sao Paulo ◽  
Retinal Function ◽  
Standard Protocol ◽  
São Paulo ◽  
State University ◽  
Veterinary Hospital

Electroretinography is a technique used for the objective assessment of retinal function and is useful as an auxiliary diagnostic tool for various ophthalmopathies. We report here information about the indications, components and measurements of the electroretinogram (ERG) and about the flash ERG technique illustrated by the Classic/Standard protocol used in the Ophthalmology Unit of the “Governador Laudo Natel” Veterinary Hospital, Faculdade de Ciências Agrárias e Veterinárias, State University of São Paulo (UNESP), Jaboticabal Campus.

Objective Assessment of Hearing in Children: Update on Procedures and Protocols

2011 ◽  
Vol 21 (2) ◽  
pp. 50-58
Author(s):  
James W. Hall ◽  
Anuradha R. Bantwal
Keyword(s):  
Psychosocial Development ◽  
Otoacoustic Emissions ◽  
Objective Assessment ◽  
Behavioral Assessment ◽  
Auditory Brainstem ◽  
Test Battery ◽  
Auditory Evoked Responses ◽  
Brainstem Response ◽  
Assessment Techniques ◽  
Pediatric Populations

Early identification and diagnosis of hearing loss in infants and young children is the first step toward appropriate and effective intervention and is critical for optimal communicative and psychosocial development. Limitations of behavioral assessment techniques in pediatric populations necessitate the use of an objective test battery to enable complete and accurate assessment of auditory function. Since the introduction of the cross-check principle 35 years ago, the pediatric diagnostic test battery has expanded to include, in addition to behavioral audiometry, acoustic immittance measures, otoacoustic emissions, and multiple auditory evoked responses (auditory brainstem response, auditory steady state response, and electrocochleography). We offer a concise description of a modern evidence-based audiological test battery that permits early and accurate diagnosis of auditory dysfunction.

Fifth Edition: the New Standard

2000 ◽  
Vol 5 (6) ◽  
pp. 1-7
Author(s):  
Christopher R. Brigham ◽  
James B. Talmage ◽  
Leon H. Ensalada
Keyword(s):  
Musculoskeletal System ◽  
Medical Information ◽  
Objective Assessment ◽  
Scientific Data ◽  
Practical Application ◽  
Fourth Edition ◽  
Appropriate Use ◽  
Medical Evaluation ◽  
Single Set

Abstract The AMA Guides to the Evaluation of Permanent Impairment (AMA Guides), Fifth Edition, is available and includes numerous changes that will affect both evaluators who and systems that use the AMA Guides. The Fifth Edition is nearly twice the size of its predecessor (613 pages vs 339 pages) and contains three additional chapters (the musculoskeletal system now is split into three chapters and the cardiovascular system into two). Table 1 shows how chapters in the Fifth Edition were reorganized from the Fourth Edition. In addition, each of the chapters is presented in a consistent format, as shown in Table 2. This article and subsequent issues of The Guides Newsletter will examine these changes, and the present discussion focuses on major revisions, particularly those in the first two chapters. (See Table 3 for a summary of the revisions to the musculoskeletal and pain chapters.) Chapter 1, Philosophy, Purpose, and Appropriate Use of the AMA Guides, emphasizes objective assessment necessitating a medical evaluation. Most impairment percentages in the Fifth Edition are unchanged from the Fourth because the majority of ratings currently are accepted, there is limited scientific data to support changes, and ratings should not be changed arbitrarily. Chapter 2, Practical Application of the AMA Guides, describes how to use the AMA Guides for consistent and reliable acquisition, analysis, communication, and utilization of medical information through a single set of standards.

390: The Use of Validated Scoring Systems to Improve Objective Assessment of Comorbid Risk in Men with Localised Prostate Cancer

2004 ◽  
Vol 171 (4S) ◽  
pp. 102-103
Author(s):  
Rajinder Singh ◽  
Declan Cahill ◽  
Rick Popert ◽  
Ronald Beaney ◽  
Anthony Wierzbicki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Objective Assessment ◽  
Scoring Systems

Canadian Objective Assessment of Life Skills

2013 ◽  
Author(s):  
Stephanie A. McDermid Vaz ◽  
R. Walter Heinrichs ◽  
Ashley A. Miles ◽  
Narmeen Ammari ◽  
Suzanne Archie ◽  
...  
Keyword(s):  
Life Skills ◽  
Objective Assessment

The Anticoagulant Effect of Heparinoid Org 10172 During Haemodialysis: An Objective Assessment

1986 ◽  
Vol 55 (02) ◽  
pp. 271-275 ◽  
Author(s):  
Helen Ireland ◽  
D A Lane ◽  
Angela Flynn ◽  
E Anastassiades ◽  
J R Curtis
Keyword(s):  
Renal Failure ◽  
Bolus Dose ◽  
Bolus Injection ◽  
Objective Assessment ◽  
Factor Xa ◽  
Fibrin Clot ◽  
Natural Origin ◽  
Fibrin Formation ◽  
Single Bolus Injection

SummaryThe heparinoid of natural origin Org 10172 has anti-factor Xa activity but minimal anti-thrombin activity, and little effect upon broad spectrum assays such as the KCCT in vitro. Its anticoagulant effects have been compared to those of commercial heparin in 7 patients undergoing haemodialysis for chronic renal failure. Commercial heparin was administered in a dose (5,000 iu bolus + 1,500 iu/hour continuous iv infusion) previously shown to inhibit fibrin formation during haemodialysis. This produced mean anti-factor Xa levels in plasma between 0.7-1.0 iu/ml and largely suppressed fibrin formation for 5 h dialysis measured as mean FPA levels in plasma. Administration of Org 10172 as a bolus of 1,350 anti-factor Xa u or 2,000-2,400 anti-factor Xa u produced plasma anti-factor Xa levels of less than 0.5 u/ml and allowed fibrin clot and FPA generation during dialysis. Org 10172 administered as a bolus dose of 4,000-4,800 anti-factor Xa u produced mean anti-factor Xa levels of greater than 0.5 u/ml, allowed dialysis of 6 patients for 5 h and appreciably suppressed FPA generation during dialysis, with little effect on the KCCT.It is concluded that the anti-factor Xa activity of Org 10172 may reflect its ability to inhibit fibrin during dialysis and that single bolus injection of Org 10172 may be a useful alternative method of achieving anticoagulation.

Sign in / Sign up

Export Citation Format

Share Document